GlassScriptPhysician profile
Polly Bittle
NPI 1134526262
$62,743.36
in general payments reported to CMS, 2019-2025
35 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,175 · 2022: $2,235 · 2023: $15K · 2024: $20K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $9,769 · Honoraria: $9,300 · Food and Beverage: $8,994 · Travel and Lodging: $5,488 · Education: $56.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,725.00 |
| Consulting Fee | $9,769.47 |
| Honoraria | $9,300.00 |
| Food and Beverage | $8,993.86 |
| Travel and Lodging | $5,488.17 |
| Education | $56.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36,064.55 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Horizon Therapeutics Plc | $14,028.11 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $3,550.89 | 2021-2025 | Farxiga, Lokelma, Evusheld |
| Calliditas Therapeutics US INC. | $3,280.90 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $1,101.12 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $1,042.30 | 2021-2025 | Acthar, Terlivaz |
| Corcept Therapeutics | $481.76 | 2024-2025 | Korlym |
| Travere Therapeutics, INC. | $326.52 | 2022-2025 | |
| Glaxosmithkline, LLC. | $325.67 | 2022-2024 | Jesduvroq, Benlysta |
| Medtronic, INC. | $320.27 | 2024 | Reveal Linq |
| Lilly USA, LLC | $260.20 | 2021-2025 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $211.30 | 2021-2024 | Jynarque |
| Lexicon Pharmaceuticals, INC. | $205.36 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.84 | 2023-2025 | Jardiance |
| Esperion Therapeutics, INC. | $137.19 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $134.87 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $133.36 | 2025 | Austedo Xr |
| Cvrx, INC. | $122.01 | 2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $121.85 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $120.48 | 2023 | Evkeeza |
| Argenx US, INC. | $115.75 | 2025 | Vyvgart |
| Ani Pharmaceuticals, INC. | $67.07 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $57.23 | 2025 | Ozempic |
| Ardelyx, INC. | $57.19 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $43.18 | 2021 | |
| Alnylam Pharmaceuticals INC. | $41.30 | 2021 | |
| Boston Scientific Corporation | $40.00 | 2023 | |
| Cycle Pharmaceuticals INC | $24.75 | 2024-2025 | Venxxiva, Tiopronin |
| Akebia Therapeutics INC | $22.79 | 2023 | Auryxia |
| Renalytix Ai, INC. | $22.03 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Dexcom, INC. | $21.74 | 2024 | Dexcom G6 Transmitter |
| Cormedix INC. | $19.23 | 2024 | Defencath |
| Scpharmaceuticals INC. | $19.17 | 2025 | |
| Aurinia Pharma U.S., INC. | $15.73 | 2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Polly Bittle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.